| Pulmonary Embolism
Pradaxa vs Savaysa
Side-by-side clinical, coverage, and cost comparison for pulmonary embolism.Deep comparison between: Pradaxa vs Savaysa with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsSavaysa has a higher rate of injection site reactions vs Pradaxa based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Savaysa but not Pradaxa, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Pradaxa
Savaysa
At A Glance
Oral
Twice daily
Direct thrombin inhibitor
Oral
Daily
Factor Xa inhibitor
Indications
- Atrial Fibrillation
- Deep Vein Thrombosis
- Pulmonary Embolism
- Nonvalvular atrial fibrillation
- Deep Vein Thrombosis
- Pulmonary Embolism
Dosing
Atrial Fibrillation CrCl > 30 mL/min: 150 mg orally twice daily; CrCl 15-30 mL/min: 75 mg orally twice daily; reduce to 75 mg twice daily if CrCl 30-50 mL/min with concomitant dronedarone or systemic ketoconazole.
Deep Vein Thrombosis, Pulmonary Embolism Treatment: 150 mg orally twice daily after 5-10 days of parenteral anticoagulation (CrCl > 30 mL/min); recurrence reduction: 150 mg orally twice daily after previous treatment (CrCl > 30 mL/min).
Prophylaxis of DVT and PE Following Hip Replacement Surgery 110 mg orally on day 1 (1-4 hours after surgery and after hemostasis), then 220 mg once daily for 28-35 days (CrCl > 30 mL/min).
Pediatric VTE Weight-based dosage orally twice daily after at least 5 days of parenteral anticoagulant (ages 8 to <18 years); adjust dose per actual weight as treatment progresses.
Nonvalvular atrial fibrillation 60 mg orally once daily in patients with CrCL >50 to <=95 mL/min; reduce to 30 mg once daily for CrCL 15-50 mL/min; do not use in patients with CrCL >95 mL/min.
Deep Vein Thrombosis, Pulmonary Embolism 60 mg orally once daily following 5-10 days of initial parenteral anticoagulant therapy; reduce to 30 mg once daily for CrCL 15-50 mL/min, body weight <=60 kg, or concomitant use of certain P-gp inhibitors.
Contraindications
- Active pathological bleeding
- History of serious hypersensitivity reaction to dabigatran, dabigatran etexilate, or any excipient (e.g., anaphylactic reaction or anaphylactic shock)
- Mechanical prosthetic heart valve
- Active pathological bleeding
Adverse Reactions
Most common Bleeding events (major and minor), gastrointestinal adverse reactions (dyspepsia, nausea, vomiting, upper abdominal pain, diarrhea, gastritis-like symptoms)
Serious Intracranial hemorrhage, major gastrointestinal hemorrhage, anaphylactic reaction, anaphylactic shock
Postmarketing Agranulocytosis, neutropenia, thrombocytopenia, esophageal ulcer, angioedema, anticoagulant-related nephropathy, alopecia
Most common (>=1%) Rash, abnormal liver function tests, anemia
Serious Intracranial hemorrhage, gastrointestinal bleeding, fatal bleeding
Postmarketing Thrombocytopenia, abdominal pain, angioedema, hypersensitivity, dizziness, headache, anticoagulant-related nephropathy, urticaria
Pharmacology
Dabigatran and its acyl glucuronides are competitive, direct thrombin inhibitors that prevent thrombus formation by blocking thrombin-mediated conversion of fibrinogen to fibrin and inhibiting thrombin-induced platelet aggregation, acting on both free and clot-bound thrombin.
Edoxaban is a selective inhibitor of factor Xa (FXa) that does not require antithrombin III for antithrombotic activity; inhibition of FXa in the coagulation cascade reduces thrombin generation and thrombus formation.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Pradaxa
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (9/12) · Qty limit (9/12)
Savaysa
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (4/12) · Qty limit (9/12)
UnitedHealthcare
Pradaxa
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (1/8) · Qty limit (1/8)
Savaysa
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (1/8) · Qty limit (4/8)
Humana
Pradaxa
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (2/3)
Savaysa
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Pradaxa.
No savings programs available for Savaysa.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
PradaxaView full Pradaxa profile
SavaysaView full Savaysa profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.